is the Scientific Director of the Non-clinical Development Program in SRI International’s Biosciences Division. Dr. Chang received her BA in mammalian physiology, MA in bioradiology, and PhD in radiation biology/biophysics from the University of California, Berkeley. She is the principal investigator (PI) on a number of National Institute of Health, National Aeronautics and Space Administration, Biomedical Advanced Research and Development Authority (BARDA), and commercially-sponsored projects, using both in vitro and in vivo model systems to understand mechanisms of radiation injury and efficacy of medical countermeasures. As PI for the National Institute of Allergy and Infectious Diseases-supported medical countermeasure product development program, she and her team conducted a battery of studies that contributed to the Food and Drug Administration’s approval of Romiplostim for hematopoietic syndrome under the Animal Rule. During her tenure at SRI, Dr. Chang has led multiple nonclinical product development programs for vaccines, biologics, metal decorporation agents, and small molecules that have resulted in over 10 approved investigational new drug applications. In collaboration with a team of SRI investigators, she is working on a BARDA-funded biodosimetry project to develop a hand-held field-deployable device for early detection of radiation exposure and triage. She has served on NCRP Scientific Committees for Report No. 181 on the evaluation of the biological effectiveness of low energy photons and electrons in inducing cancers in humans and Report No. 183 on radiation exposure in space and the potential for central nervous system effects.